Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chubb
Julphar
Johnson and Johnson
Cipla
Deloitte
Mallinckrodt
US Department of Justice
Federal Trade Commission
Harvard Business School

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,668,931

« Back to Dashboard

Summary for Patent: 8,668,931
Title:Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
Inventor(s): Kositprapa; Unchalee (Davie, FL), Goldfarb; Robert I. (Golden Beach, FL), Cardinal; John R. (Tamarac, FL), Nangia; Avinash (Weston, FL)
Assignee: Actavis, Inc. (Parsippany, NJ)
Application Number:13/889,441
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Device;

Drugs Protected by US Patent 8,668,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-001 May 12, 2009 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-002 May 12, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,668,931

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,785,627 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
8,309,125 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
8,470,368 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
9,060,941 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
7,959,946 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
8,084,058 Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,668,931

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 91852 ➤ Sign Up
Taiwan I361070 ➤ Sign Up
Taiwan 200529831 ➤ Sign Up
Taiwan I344375 ➤ Sign Up
Taiwan 200718433 ➤ Sign Up
Singapore 160415 ➤ Sign Up
Peru 13892006 ➤ Sign Up
New Zealand 580804 ➤ Sign Up
New Zealand 561124 ➤ Sign Up
New Zealand 545653 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
US Army
Harvard Business School
Moodys
McKesson
Baxter
Colorcon
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot